ClinicalTrials.gg
CompletedNCT04874233Updated Mar 1, 2024Results posted

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

A Phase 2 interventional study of HU6 and Placebo in NASH - Nonalcoholic Steatohepatitis, sponsored by Rivus Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 28 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by Rivus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
28 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
181st of 460
80 · median 56
Started
2021
with 56 others
Phase 2
192 of 547
15 open now
Registered
397th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 181st largest by enrollment of the 460 interventional ones that give a count, is one of 57 that started in 2021, is one of 192 in phase 2, and was the 397th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 28 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.

Read the detailed description

This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.

Subjects will be screened over a 45 day period to determine their eligibility based on specific history, physical, laboratory and imaging evaluations as per the Schedule of Assessments. Due to scheduling of the procedures, multiple visits will likely be necessary to complete the screening process. However, if all screening assessments and procedures, including the MRI, can be completed within 30 days of the first dose, then a single screening visit is permissible.

03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
28 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Adult male or females, 28 to 65 years of age (inclusive) at the time of with between 28.0 and 45.0 kg/m2 (inclusive).

      1. Female subjects of must be non-lactating, not pregnant as confirmed by a negative urine pregnancy test at Screening and agree to continue using an effective method of for at least 4 weeks or barrier method for 2 weeks prior to first study drug administration until 30 days after the last dose of study drug (Section 8.3.2).
      2. Female subjects of childbearing potential must not donate ova during the study and for at least 30 days after the last dose of study drug.
      3. Female subjects of non-childbearing potential must be surgically sterile (e.g., hysterectomy, bilateral tubal ligation, oophorectomy) or (no menses for >1 year with follicle stimulating hormone (FSH) >40 U/L at Screening).
      4. Male subjects who have not had a vasectomy and/or subjects who have had a vasectomy but have not had 2 post surgery negative tests for sperm must agree to use an acceptable method of contraception from time of first dose of study drug until 30 days after the last dose of the study drug, and to not donate sperm during the study and for at least 30 days after the last dose of study drug.

        1. Inclusion as per investigator assessment of general medical status and as documented by medical history, physical examination, vital sign assessments, 12-lead , clinical laboratory assessments, and general observations.

      <!-- -->

      1. Subjects must be on stable doses of medications for underlying obesity-related conditions for at least 2 months prior to screening.
      2. Subjects with diabetes may be treated with metformin, DPP-4 inhibitors, or sulfonylureas, but must be on stable doses for at least 2 months prior to screening.
      3. At Screening, certain laboratory values may be outside the reference range if commensurate with the underlying obesity or associated metabolic dysfunction in the eligible subject (for example, dyslipidemia and hyperglycemia), unless these abnormalities suggest an underlying condition which may impact subject safety in the trial or interfere with the evaluation of HU6 or affect interpretation of the study results.
      4. Abnormalities or deviations outside the normal ranges for other assessments that are considered by the Investigator (clinical laboratory tests, ECG, vital signs, physical examination) may be repeated once at the discretion of the Investigator(s). Results that continue to be outside the normal ranges must be judged by the investigator to be not clinically significant and acceptable for study participation.
      5. Subjects with elevation of unconjugated due to presumptive Gilbert's syndrome are permissible.
      6. Subject must be euthyroid as assessed by a thyroid profile utilizing thyroid stimulating hormone (TSH) and free thyroxine (T4) testing at screening. Subjects with a stable history of thyroid disease and who have been on stable doses of thyroid medications for a minimum of 4 months can be enrolled.

        1. Fibroscan® CAP score>300 dB/m. 4. ≥8% liver fat by MRI-PDFF. 5. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure.
        1. Willing and able to comply with the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

Subjects will be excluded from the study if any of the following criteria are met:

  1. Insulin-controlled diabetes.
  2. Pregnant or breastfeeding or plans to become pregnant.
  3. Intolerance to Magnetic Resonance Imaging (MRI) or with conditions for MRI procedures including but not limited to inability to fit into MRI scanner or surgical clips/metallic implants/shrapnel. Subjects must not be claustrophobic, have a history of claustrophobia, or intolerance of closed or small spaces.
  4. Weight gain or loss >5% in 3 months prior to study or >10% in 6 months prior to screening.
  5. History of lap banding, intragastric balloon, duodenal-jejunal sleeve, or bariatric surgery within 5 years of screening, plans for bariatric surgery prior to conclusion of study participation, or plans to lose weight during this study either through a special diet, exercise program or both.
  6. History of malignant hyperthermia.
  7. History of chronic serious recurrent skin rashes of unknown cause.
  8. History of or current cardiovascular disease including but not limited to , stroke, cardiac arrhythmias, syncope, unstable angina, myocardial infarction in the 6 months prior to screening, congestive heart failure, or uncontrolled hypertension. (Uncontrolled hypertension is defined as a systolic blood pressure ≥160 mmHg or a diastolic blood pressure ≥100 mmHg based on an average of three resting determinations in the sitting position with an appropriately sized cuff).
  9. Resting heart rate \<45 or >110 bpm.
  10. On screening or by history:

    1. A marked baseline prolongation of /QTcF interval (e.g., repeated demonstration of a QTcF interval > 450 msec for males and >470 msec for females).
    2. A history of additional risk factors for Torsades de Pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) or a family history of sudden cardiac death of unknown origin.
  11. Kidney disease, kidney transplant, or estimated (eGFR) \<50 mL/min/1.73 m2 based on the CKD-EPI Creatinine Equation (NKF 2009; https://www.kidney.org/content/ckd-epi-creatinine-equation-2009).
  12. Significant lung disease requiring chronic daily medication including (COPD), emphysema, pulmonary fibrosis, or asthma.
  13. Untreated obesity hypoventilation syndrome (OHS) or obstructive sleep apnea (OSA).
  14. History of or active (acute or chronic) liver disease other than nonalcoholic fatty liver disease (NAFLD)/ nonalcoholic steatohepatitis (NASH), such as but not limited to liver disease, viral hepatitis, genetic hemochromatosis, primary biliary cirrhosis, Wilson disease, alpha-1-antitrypsin deficiency, alcohol liver disease, acute fatty liver of pregnancy or drug induced (including acetaminophen) liver disease.
  15. History of or treatment for clinically significant gastroparesis, inflammatory bowel disease, or any surgery of the upper gastrointestinal tract with the exception of cholecystectomy, or minor gastric procedures that are approved by the medical monitor.
  16. History of cirrhosis and/or hepatic decompensation, including ascites, hepatic encephalopathy, or variceal bleeding.
  17. History of acute pancreatitis within one year of screening or chronic pancreatitis of any cause.
  18. Serum triglyceride concentrations exceeding 500 mg/dL.
  19. >9.0%.
  20. Familial (mother/father/sibling) and/or personal history of retinal detachment any time in the past.
  21. Any history of or current diagnosis of Glaucoma.
  22. Evidence of the following on screening ophthalmologic examination:

    1. Peripheral retinal pathology requiring treatment, retinal tears, or lattice that require treatment.
    2. Diabetic retinopathy with macula exudates or macula edema as shown by optical coherence tomography (OCT) and examination.
    3. Any active macular disease that affects the vision, including macula pucker (epiretinal membrane) and macular degeneration.
    4. Visually significant cataract as determined by ophthalmologist.
    5. Any previous intravitreal injection of anti-VEGF agents for macular degeneration.
    6. History of prior vitrectomy.
  23. History of malignant neoplasms within 5 years of screening, except for basal cell or squamous cell skin cancer, cervical carcinoma in situ, or prostate cancer that is not currently or expected to require radiation therapy, chemotherapy and/or surgical interventions or to initiate hormonal treatment.
  24. History of organ transplantation.
  25. Received a COVID-19 vaccine less than 1 week prior to dosing (Visit 2 / Day 1) and/or plans to receive a COVID-19 vaccine during the study period.
  26. History of significant drug abuse within one year prior to Screening or frequent use of soft drugs (such as marijuana) within 3 months prior to the Screening visit, or hard drugs (such as cocaine, phencyclidine [PCP], opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
  27. History of alcoholism in the last 2 years or current evidence of excessive alcohol consumption as assessed by screening evaluation using the Alcohol Use Disorders Identification Test (AUDIT, Thompson 2018 [Appendix A]), and history of regular alcohol consumption exceeding approximately 14 drinks/week for men and 7 drinks/week for women [1 drink = 4 ounces (120 mL) of wine or 12 ounces (360 mL) of beer or 1 ounce (30 mL) of hard liquor] within 6 months of Screening, as determined by the Investigator.
  28. Positive urine drug screen for drugs of abuse or positive phosphatidylethanol (PEth) blood test result >25 ng/mL at Screening.
  29. Current regular vaping or more than 5 cigarettes or the equivalent per week. Use of nicotine patches for smoking cessation is permitted.
  30. Positive test results of surface antigen (HBsAg), virus antibody (HCV Ab), or (HIV1/2) antibody.
  31. Neutropenia, defined as ≤1000/μL.
  32. Serum or ALT >5 x (ULN) at screening. (One repeat test may be allowed within 7 days at the discretion of the Investigator).
  33. Total > ULN, unless due to Gilbert's syndrome or if considered normal variability in the absence of other clinically relevant liver impairment as approved by Medical Monitor.
  34. (INR) ≥1.3 at screening if there is other evidence of potential significant liver impairment.
  35. Participation in another clinical trial at the time of screening or exposure to any agent, including topical, within 30 days of screening or 5 half-lives, if half-life known.
  36. No tattoo or body piercings during the course of the study. Any underlying physical or psychological medical condition that, in the opinion of the Investigator or sponsor, would make it unlikely that the subject is able comply with the study requirements or would be unable to complete the study.
  37. Any condition that the investigator believes would interfere with his/her ability to provide written , comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.
  38. Known or potential to HU6 or its .

    Prohibited Medications (Current Use):

  39. Any herbal supplement, over the counter drug, mail order or prescription drug for weight loss.
  40. Prescription or over the counter stimulants including: dextroamphetamine/Dexedrine, dextroamphetamine/amphetamine combination product/Adderall, or methylphenidate (Ritalin®, Concerta®).
  41. Thiazolidinediones (TZD): pioglitazone/Actos, rosiglitazone/Avandia.
  42. Glucagon-like peptide 1 (GLP1) agonists: exenatide/Byetta/Bydureon, lixisenatide/Adlyxin, liraglutide/Victoza, dulaglutide/Trulicity, semaglutide/Ozempic.
  43. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: canagliflozin/Invokana, dapagliflozin/Farxiga, empagliflozin/Jardiance, ertugliflozin/Steglatro.
  44. Vitamin E: use of ursodiol or high dose vitamin E >400 IU/day for at least one month within in the last 6 months or started high dose vitamin E within last 3 months of screening.
  45. Recent (within 3 months of screening) or current use of obeticholic acid/Ocaliva, systemic , methotrexate, tamoxifen, amiodarone, or long-term use of tetracyclines.
  46. Warfarin, heparin, factor Xa inhibitors (dabigatran betrixaban edoxaban, apixaban, and rivaroxaban).
  47. Concomitant medications that prolong the QT/QTc interval and are known to be associated with increased risk of Torsade des pointes as identified in the https://crediblemeds.org/ website list category of 'Known Risk' (Appendix B).
  48. Products with cannabidiol (CBD).
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    Active Treatment: HU6 150 mg; N = 20

    HU6 is Active Study Drug

    Drug: HU6

  • Active comparator
    Active Treatment: HU6 300 mg; N = 20

    HU6 is Active Study Drug

    Drug: HU6

  • Active comparator
    Active Treatment: HU6 450 mg; N = 20

    HU6 is Active Study Drug

    Drug: HU6

  • Placebo comparator
    Placebo Comparator Non-active study drug N = 20

    Non-active Study Drug

    Drug: Placebo

Interventions

  • DrugHU6

    Drug pages: HU6 · Dinifedriton

    HU6 is active study drug

  • DrugPlacebo

    Non-active study drug N = 20

06

What researchers measure

Primary outcomes

  1. Percentage of Change From Baseline in Liver Fat Content as Assessed by MRI-PDFF

    Percentage of Change from Baseline in Liver Fat Content as Assessed by MRI-PDFF at Day 61

    Time frame: Baseline and 61 days;

07

Results

Posted Mar 1, 2024

Participant flow

Study Start: April 19,2021, Completion: November 30,2021, Study Completion: December 15,2021 at one site

Participant flow — Overall Study
MilestoneActive Treatment: HU6 150 mgActive Treatment: HU6 300 mgActive Treatment: HU6 450 mgPlacebo Comparator Non-active Study Drug
Started20211920
Completed18201917
Not completed2103

Outcome measures

PrimaryPercentage of Change From Baseline in Liver Fat Content as Assessed by MRI-PDFF

Percentage of Change from Baseline in Liver Fat Content as Assessed by MRI-PDFF at Day 61

Time frame:
Baseline and 61 days;
Reported as:
Mean · percentage of change
Percentage of Change From Baseline in Liver Fat Content as Assessed by MRI-PDFF
percentage of changeActive Treatment: HU6 150 mgActive Treatment: HU6 300 mg;Active Treatment: HU6 450 mg;Placebo Comparator Non-active Study Drug
Percentage of Change From Baseline in Liver Fat Content as Assessed by MRI-PDFF-26.8 ± 17.4-35.6 ± 13.8-33.0 ± 18.45.4 ± 19.8

Adverse events

Collected over 61 days of dosing. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active: HU6 150mg0/20 (0%)0/20 (0%)13/20 (65%)
Active: HU6 300mg0/21 (0%)0/21 (0%)17/21 (81%)
Active: HU6 450mg0/19 (0%)0/19 (0%)16/19 (84.2%)
Placebo Comparator0/20 (0%)0/20 (0%)11/20 (55%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventActive: HU6 150mgActive: HU6 300mgActive: HU6 450mgPlacebo Comparator
FlushingVascular disorders3/208/218/192/20
DiarrhoeaGastrointestinal disorders3/206/216/190/20
PalpitationsCardiac disorders2/202/213/191/20
Night sweatsSkin and subcutaneous tissue disorders0/200/213/191/20
HeadacheNervous system disorders2/202/210/193/20
Abdominal PainGastrointestinal disorders0/201/212/190/20
DizzinessNervous system disorders2/201/212/190/20
FatigueGeneral disorders1/202/211/192/20
PyrexiaGeneral disorders0/202/211/192/20
DyspnoeaRespiratory, thoracic and mediastinal disorders2/201/211/190/20

Baseline characteristics

Age, Continuous
Age, Continuous(years)Active: HU6 150mgActive: HU6 300mgActive: HU6 450mgPlacebo ComparatorTotal
Mean46.2 ± 10.3147.1 ± 6.7846.7 ± 10.0450.7 ± 9.2447.7 ± 9.16
Sex: Female, Male
Sex: Female, Male(Participants)Active: HU6 150mgActive: HU6 300mgActive: HU6 450mgPlacebo ComparatorTotal
Female10128939
Male109111141
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Active: HU6 150mgActive: HU6 300mgActive: HU6 450mgPlacebo ComparatorTotal
Hispanic or Latino13004
Not Hispanic or Latino1918192076
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Active: HU6 150mgActive: HU6 300mgActive: HU6 450mgPlacebo ComparatorTotal
American Indian or Alaska Native00011
Asian40116
Native Hawaiian or Other Pacific Islander00000
Black or African American01012
White1519171768
More than one race11103
Unknown or Not Reported00000
Liver fat content, as assessed by MRI-PDFF
Liver fat content, as assessed by MRI-PDFF(percentage of liver fat mass)Active: HU6 150mgActive: HU6 300mgActive: HU6 450mgPlacebo ComparatorTotal
Mean18.6 ± 6.918.0 ± 8.217.3 ± 8.215.9 ± 5.917.7 ± 7.23
08

Study locations

1 site
  • Prism Clinical Research
    Minneapolis, Minnesota 55114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Nov 2021, 7 months.

Results were first posted in Mar 2024, 2 years 3 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 7 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2021
First posted
May 5, 2021
StartActual
Apr 19, 2021
Primary completionActual
Nov 30, 2021
CompletionActual
Dec 15, 2021
Results first posted
Mar 1, 2024
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04874233
Lead sponsor
Rivus Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 5, 2021
Start date
Apr 19, 2021
Primary completion
Nov 30, 2021
Completion
Dec 15, 2021
Results posted
Mar 1, 2024
Last update
Mar 1, 2024

Study contacts

Amy Eastenson
principal investigator · Prism Clinic Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HU6 · Dinifedriton

Start the discussion